MedTrace Logo

A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Linifanib (ABT-869)

NCT01114191 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2011-07-26

No results posted yet for this study

Summary

This is a phase 1, open-label study designed to determine the interaction of ketoconazole with ABT-869.

Conditions

Interventions

DRUG

ABT-869

2.5mg \[5 mg days 1, 8 and 12. 17.5 mg on days 13 and after\]

DRUG

ketoconazole

400 mg days 6-11

Sponsors & Collaborators

Principal Investigators

  • Mark D McKee, MD · Abbott

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01114191 on ClinicalTrials.gov